2011
DOI: 10.1590/s1678-91992011000400004
View full text | Cite
|
Sign up to set email alerts
|

Abstract: Abstract:Staphylococcus aureus and coagulase-negative Staphylococcus (CoNS) are frequently found in nosocomial environments as the main pathogen in several infections. In 1961, reports of nosocomial S. aureus resistant to methicillin, the drug of choice against penicillin-resistant strains, required new alternatives and vancomycin started being used to treat infections caused by methicillin-resistant S. aureus (MRSA). Community-acquired methicillin-resistant S. aureus (CA-MRSA) was first reported in 1990 affec… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 56 publications
(68 reference statements)
0
2
0
Order By: Relevance
“…ETA is an SGB prophage-encoded virulence factor and was present among all MRSA strains harboring this prophage type. SAK is a 16-kDa prophage-encoded protein, which acts as a fibrin-specific activator of human plasminogen produced by certain S. aureus strains, which indicates the proteolytic activity of MRSA strains (33). We found that 93% of MRSA strains isolated from different clinical samples such as urine, wound, sputum and cerebrospinal fluid (CSF) were positive for sak gene, which is higher than the previous report from Iran (18).…”
Section: Discussionmentioning
confidence: 62%
“…Nosocomial strains of MRSA are typically multi-resistant and are associated with SCCmec type I, II or III, which comprise genes that code for resistance to various classes of antibiotics [ 29 , 30 , 31 , 32 , 33 ]. These strains are usually treated with a combination of two oral antimicrobials [ 34 ]; however, the escalation of divergent resistant phenotypes has created a need to develop new therapeutic alternatives, preferentially with lower hazardous side effects.…”
Section: Discussionmentioning
confidence: 99%